Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):321-325. doi: 10.1016/j.diagmicrobio.2019.03.003. Epub 2019 Mar 23.

2.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.

3.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
4.

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.

Hackel MA, Iaconis JP, Karlowsky JA, Sahm DF.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01892-17. doi: 10.1128/JCM.01892-17. Print 2018 Apr.

5.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01968-17. doi: 10.1128/AAC.01968-17. Print 2018 Feb.

6.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.

7.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

Karlowsky JA, Hackel MA, Bouchillon SK, Alder J, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):151-157. doi: 10.1016/j.diagmicrobio.2017.07.001. Epub 2017 Jul 8.

PMID:
28793964
8.

Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide.

Hackel MA, Karlowsky JA, Dressel D, Sahm DF.

J Clin Microbiol. 2017 Oct;55(10):3021-3027. doi: 10.1128/JCM.00972-17. Epub 2017 Jul 26.

9.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17. doi: 10.1128/AAC.00472-17. Print 2017 Sep.

10.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00093-17. doi: 10.1128/AAC.00093-17. Print 2017 Sep.

11.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

Braz J Infect Dis. 2017 May - Jun;21(3):343-348. doi: 10.1016/j.bjid.2017.03.006. Epub 2017 Apr 8.

12.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

13.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
14.

Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

J Med Microbiol. 2017 Jan;66(1):61-69. doi: 10.1099/jmm.0.000421. Epub 2017 Feb 22.

PMID:
28051952
15.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Biedenbach DJ, Hackel MA, Quintana A, Wible M, Dowzicky MJ, McGovern PC, Bouchillon SK.

J Glob Antimicrob Resist. 2015 Dec;3(4):311-312. doi: 10.1016/j.jgar.2015.09.004. Epub 2015 Oct 22. No abstract available.

PMID:
27842883
16.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014.

Lob SH, Badal RE, Hackel MA, Sahm DF.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):72-79. doi: 10.1093/jpids/piv109.

PMID:
26883618
17.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

Kazmierczak KM, Lob SH, Hoban DJ, Hackel MA, Badal RE, Bouchillon SK.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):209-14. doi: 10.1016/j.diagmicrobio.2015.03.025. Epub 2015 Apr 9.

PMID:
25956930
18.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.

Surg Infect (Larchmt). 2015 Jun;16(3):298-304. doi: 10.1089/sur.2014.060. Epub 2015 Apr 20.

PMID:
25894976
19.

Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF.

Antimicrob Agents Chemother. 2015;59(6):3606-10. doi: 10.1128/AAC.05186-14. Epub 2015 Mar 23.

20.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
22.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ.

Surg Infect (Larchmt). 2013 Apr;14(2):203-8. doi: 10.1089/sur.2012.034. Epub 2013 Mar 29.

PMID:
23540793
23.

Molecular characterization of methicillin-susceptible Staphylococcus aureus clinical isolates in the United States, 2004 to 2010.

Miko BA, Hafer CA, Lee CJ, Sullivan SB, Hackel MA, Johnson BM, Whittier S, Della-Latta P, Uhlemann AC, Lowy FD.

J Clin Microbiol. 2013 Mar;51(3):874-9. doi: 10.1128/JCM.00923-12. Epub 2013 Jan 2.

24.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.

J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.

PMID:
22546718

Supplemental Content

Loading ...
Support Center